Eyepoint Pharmaceuticals’ (EYPT) “Neutral” Rating Reiterated at Mizuho

Mizuho reiterated their neutral rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a report released on Tuesday morning, MarketBeat Ratings reports. They currently have a $0.50 price objective on the stock.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. Royal Bank Of Canada restated a “sector perform” rating and set a $5.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Jefferies Financial Group cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a report on Monday. Stifel Nicolaus started coverage on shares of Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Monday, August 17th. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Eyepoint Pharmaceuticals presently has an average rating of “Hold” and an average target price of $21.85.

Eyepoint Pharmaceuticals Stock Down 0.4%

Eyepoint Pharmaceuticals stock opened at $0.43 on Tuesday. The firm has a market cap of $36.91 million, a price-to-earnings ratio of -0.11 and a beta of 1.67. Eyepoint Pharmaceuticals has a 52 week low of $0.39 and a 52 week high of $19.11. The business’s 50-day moving average price is $3.99 and its 200 day moving average price is $10.03.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The company had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Equities analysts expect that Eyepoint Pharmaceuticals will post -3.50 EPS for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors have recently modified their holdings of EYPT. Janus Henderson Group PLC increased its stake in shares of Eyepoint Pharmaceuticals by 22.6% during the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after purchasing an additional 663,439 shares in the last quarter. Commodore Capital LP purchased a new position in Eyepoint Pharmaceuticals in the 1st quarter valued at about $36,414,000. Hsbc Holdings PLC purchased a new position in Eyepoint Pharmaceuticals in the 1st quarter valued at about $10,743,000. Stempoint Capital LP boosted its holdings in Eyepoint Pharmaceuticals by 129.1% in the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after buying an additional 456,915 shares during the last quarter. Finally, Principia Wealth Advisory LLC boosted its holdings in Eyepoint Pharmaceuticals by 2.6% in the 2nd quarter. Principia Wealth Advisory LLC now owns 649,944 shares of the company’s stock worth $9,294,000 after buying an additional 16,180 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its Q3 2027 EPS forecast to $0.45 from a projected loss of $0.45, suggesting the analyst still sees a potential path to profitability in the longer term. However, the firm maintained a Neutral rating. HC Wainwright estimates
• Neutral Sentiment: Several firms maintained cautious views: HC Wainwright reaffirmed Neutral, Mizuho assigned Neutral, and Laidlaw reaffirmed Hold. These ratings indicate limited conviction in a near-term recovery following the clinical setback. HC Wainwright rating Mizuho rating Laidlaw rating
• Neutral Sentiment: Large call-option activity suggests some traders are positioning for a rebound, but options activity is speculative and does not change the company’s fundamental outlook. EyePoint call options
• Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS estimate to a loss of $0.85 from $0.60 and cut its FY2026 estimate to a loss of $3.40 from $3.15, reflecting worsening near-term expectations. Revised EPS estimates
• Negative Sentiment: JPMorgan issued an Underweight rating, while Jefferies and Guggenheim downgraded the stock, adding further institutional pressure after the failed LUCIA trial. JPMorgan rating Jefferies downgrade Guggenheim downgrade
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities claims related to the LUCIA trial disclosure and the resulting shareholder losses. The investigation adds legal and reputational risk, although it does not establish wrongdoing. Levi & Korsinsky investigation

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.